Abolis Biotechnologies
- Company typePrivate
- Founded2014
- HeadquartersÉvry, France
- Headcount51–100
- GTM typeB2B
- OfferingServices
Abolis Biotechnologies firmographics
Firmographics- Name
- Abolis Biotechnologies
- Legal name
- ABOLIS
- Website
- https://abolis.fr
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Abolis Biotechnologies industry classification
Industry- Product category
- Industrial Biotechnology Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Industrial Organic Chemicals (2860), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)
- akta.pro secondary industries
- Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Biological Formulation, Fermentation & Scale-Up Manufacturing (AFABAEAM), Bio-based Food & Flavor Ingredients (Non-fuel Co-products: sweeteners, organic acids, flavors) (EUAAAIAJ), Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE)
Keywords
Where Abolis Biotechnologies is headquartered
LocationHeadquarters
- HQ city
- Évry
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Abolis Biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
Revenue model
- Custom Microbial Solutions Services: End-to-end solutions for bio-based product innovation including strain engineering, bioprocess development, and industrial scale-up. Projects tailored to client needs across pharmaceutical, cosmetic, nutrition, and chemical industries.
- Microbiome Studio SaaS: Software-as-a-service platform for microbiome analysis and metabolic network visualization. Offered in two modes: full SaaS access with team training, or service mode where the Microbiome Studio team builds projects from client briefs.
- Strategic Industrial Partnerships: Long-term strategic partnerships with industry leaders like L'Oréal and Evonik for joint product development and commercialization across multiple sectors.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Microbiome Studio SaaS Mode |
| Hybrid | Project-based | Microbiome Studio Service Mode |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Abolis Biotechnologies product offering
Product offeringCore offering
Abolis provides tailor-made industrial biosolutions based on microorganisms, delivering end-to-end microbial biotechnology services covering strain engineering, microbiome deciphering, bioprocess development, and industrial scale transfer. The company combines synthetic biology, proprietary genetic tools, fermentation technologies, and machine learning to design custom microorganisms that produce bio-based ingredients for pharmaceutical, cosmetic, nutrition, and specialty chemical applications. Its Microbiome Studio SaaS platform enables metabolic network analysis and visualization for microbiome-based product innovation.
Product overview
Abolis Biotechnologies offers a unified portfolio comprising two core platforms: Microbiome Studio (a SaaS solution for microbiome analysis and metabolic network visualization) and Industrial Biotech (end-to-end microbial fermentation solutions). These are supported by four integrated service modules—Strain Engineering, Microbiome Deciphering, Bioprocess Development, and Industrial Scale Transfer—that collectively enable bio-based product innovation across Healthcare, Cosmetic, Nutrition & Agriculture, and Specialty Chemicals industries. The company leverages advanced genetic tools, Machine Learning, and fermentation technologies to design custom microorganisms for sustainable and cost-effective production.
Differentiator
Problem solved
Functional benefit
Brands
- Microbiome Studio: A SaaS solution for analysis and visualization of metabolic networks, graphical metabolic maps, and strain/ecosystem selection for microbiome-based product innovation.
Products and services
- Microbiome Studio A SaaS platform for analysis and visualization of metabolic networks, providing tools for multi-omics data processing, graphical metabolic mapping, and ML-driven strain and ecosystem selection for microbiome-based product innovation. Available in SaaS mode (self-service with own datasets) and Service mode (project built by the Microbiome Studio team). Targeted at biotech and pharmaceutical R&D teams.
- Industrial Biotech End-to-end microbial biotechnology solutions covering strain selection and engineering, bioprocess development, strain optimization, and industrial transfer. Supports production of bio-based ingredients through fermentation technologies for pharmaceutical, cosmetic, nutrition, and specialty chemical customers.
- Strain Engineering Strategic identification of high-potential strains using Abolis's proprietary strain collection and development of cutting-edge genetic tools for rapid and precise microorganism domestication. Includes initial Techno Economic Assessment to evaluate industrial viability. Targeted at companies seeking custom microbial production hosts.
- Microbiome Deciphering Analysis and engineering of microbial ecosystems using advanced data science and machine learning to understand strain metabolism and identify optimal candidates for microbiome-based product innovation. Targeted at biotech and industrial R&D teams developing microbiome-based products.
- Bioprocess Development Designing fermentation processes and nutrient media to maximize product yield, implementing real-time sensors and strong analytical platforms, and optimizing fermentation parameters at scale-up conditions. Targeted at companies scaling bio-based production processes.
- Industrial Scale Transfer Fermentation optimization from lab to 20L scale with trusted partners for pilot to industrial scale manufacturing, providing one-stop support from concept to commercial production of bio-based ingredients. Targeted at enterprises requiring commercial-scale fermentation capacity.
Quantifiable outcome
- Nearly 80% of global corticosteroid market currently controlled by Asian producers, providing significant market opportunity for European production
- +1 more outcomes
Companies that use Abolis Biotechnologies
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles5 records
Abolis Biotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Abolis Biotechnologies partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor, core and supporting.
- Booster Grow Global KSAminorParticipation in fourth edition of program strengthening technological collaborations between France and Saudi Arabia. Aligns with Saudi Vision 2030 for economic diversification and ecological transition.
- EUROAPIcoreStrategic partnership as part of IPCEI Med4Cure program (up to €140 million public support via France 2030). Abolis develops microbial strains and bioprocesses for corticosteroid production to restore European pharmaceutical sovereignty. Production at EUROAPI sites in Normandy and Auvergne. Four-year collaboration with funding from Bpifrance and EUROAPI.
- Institute of Chemistry for Health at Chimie Paris TechsupportingAcademic partner in Med4Cure IPCEI program bringing together innovative companies and leading academic teams for pharmaceutical sovereignty.
- CARMEN laboratory at INSA RouensupportingAcademic partner in Med4Cure IPCEI program contributing to corticosteroid production development research.
- CEISAM laboratory at University of NantessupportingAcademic partner in Med4Cure IPCEI program supporting pharmaceutical innovation research.
- Toulouse INPsupportingAcademic partner in Med4Cure IPCEI program contributing to pharmaceutical development expertise.
- L'OréalcoreStrategic partnership with Abolis and Evonik to develop bio-based ingredients for cosmetics. Goal to reduce industry carbon footprint and enhance sustainability in raw material sourcing. Involves research, development, and production of environmentally friendly ingredients. Supported by €35 million investment round.
- EvonikcoreStrategic partnership with L'Oréal and Abolis for developing bio-based ingredients across cosmetic, nutrition and healthcare sectors. Evonik contributes expertise in fermentation processes, downstream processing and scale-up for commercial production. Lead investor in €35 million funding round.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Abolis Biotechnologies competitors and assessment
Company assessmentDirect peers
- Conagen: US-based strain engineering and fermentation CDMO that develops custom microorganisms to produce bio-based ingredients across food, nutrition, cosmetics and pharma. Directly comparable to Abolis in offering tailor-made microbial solutions for industrial customers.
- Codexis: Specialist in engineered enzymes and microbial strains for pharmaceutical and industrial applications. Highly comparable to Abolis in combining proprietary protein/strain engineering with bioprocess development and customer-funded scale-up.
- Bota Bio: AI-driven synthetic biology platform that designs and scales microbial fermentation for chemicals, nutrition and personal care. Closely mirrors Abolis's positioning of computational biology plus industrial fermentation for bio-based ingredients.
Broad incumbents
- Ginkgo Bioworks: Largest publicly listed synthetic biology platform, engineering microbes for industrial applications across multiple end-markets. A broader incumbent whose Cell Engineering and Biosecurity offerings overlap with Abolis's strain engineering and microbiome analytics capabilities.
- LanzaTech: Industrial biotech company commercializing gas-fermentation at scale for fuels and chemicals, with strategic partnerships across consumer goods. A broader incumbent in industrial fermentation whose commercial model mirrors Abolis's customer-funded scale-up approach.
- Novonesis: Global enzyme and microbial solutions leader (post Novozymes-Christian Hansen merger) serving food, health and industrial markets. Establishes the incumbent benchmark that Abolis competes against in bio-based ingredients and fermentation services.
- dsm-firmenich: Global nutrition, health and beauty ingredients giant combining fermentation, bioprocess and formulation capabilities. A large established player whose specialty ingredients and bio-based alternatives directly overlap with Abolis's customer offerings in nutrition and cosmetics.
Emerging players
- Cradle: Amsterdam-based ML platform for protein and enzyme design sold to industrial biotech and pharma R&D teams. Adjacent to Abolis's Microbiome Studio SaaS, addressing similar ML-for-biology use cases in industrial settings.
- Debut Biotech: US cell-free biomanufacturing startup developing sustainable ingredients for cosmetics and pharma, partnered with L'Oréal. Directly comparable to Abolis in pursuing bio-based cosmetic ingredients through L'Oréal's venture and open-innovation ecosystem.
- Carbios: French industrial biotech using engineered enzymes for plastics recycling and bio-based polymers. A regional emerging peer with similar French biocluster presence and an industrial-biotech commercialization model comparable to Abolis's.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Abolis Biotechnologies social profiles
Digital presenceAbolis Biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Abolis Biotechnologies leadership team
Management profileNumber of profiles
Profiles6 records
Abolis Biotechnologies funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Abolis Biotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Abolis Biotechnologies
What does Abolis Biotechnologies do?
Abolis provides tailor-made industrial biosolutions based on microorganisms, delivering end-to-end microbial biotechnology services covering strain engineering, microbiome deciphering, bioprocess development, and industrial scale transfer. The company combines synthetic biology, proprietary genetic tools, fermentation technologies, and machine learning to design custom microorganisms that produce bio-based ingredients for pharmaceutical, cosmetic, nutrition, and specialty chemical applications. Its Microbiome Studio SaaS platform enables metabolic network analysis and visualization for microbiome-based product innovation.
Is Abolis Biotechnologies a public or private company?
Abolis Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was Abolis Biotechnologies founded?
Abolis Biotechnologies was founded in 2014. It employs 51 to 100 people.
Where is Abolis Biotechnologies based?
Abolis Biotechnologies is headquartered in Évry, France, in the Europe region.
How does Abolis Biotechnologies make money?
Three revenue lines are on record. Custom Microbial Solutions Services are the primary driver. The others are microbiome Studio SaaS and strategic Industrial Partnerships.
Who are Abolis Biotechnologies's main competitors?
Direct peers on record are Conagen, Codexis and Bota Bio. Broad incumbents are Ginkgo Bioworks, LanzaTech, Novonesis and dsm-firmenich. Emerging players are Cradle, Debut Biotech and Carbios.
Does Abolis Biotechnologies have an API?
No public API is recorded for Abolis Biotechnologies.
What industry is Abolis Biotechnologies in?
Abolis Biotechnologies's product category is Industrial Biotechnology Services. Its primary akta.pro industry code is HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery), with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 541714 and its SIC code is 2860.